Introduction
============

With the development of interventional technology and medication strategies, the number of cardiac catheterization procedures being performed continues to grow rapidly.[@b1-tcrm-13-887] Simultaneously, the incidence of contrast-induced nephropathy (CIN), a common and well-known complication which occurs following coronary angiography (CAG) or percutaneous coronary intervention (PCI) and is significantly associated with renal and cardiovascular adverse events and long-term mortality, has also increased gradually.[@b2-tcrm-13-887],[@b3-tcrm-13-887] Since the effective treatment measures for CIN are unknown, risk identification is important for ensuring that high-risk patients receive appropriate prophylactic measures and postoperative monitoring.[@b4-tcrm-13-887]

Heart failure (HF) is a common and deteriorating condition, which has a high prevalence of ischemic origin.[@b5-tcrm-13-887] With the advancement of HF or cardiac impairment, adverse hemodynamic state results in inadequate renal perfusion and accelerates the renal impairment after contrast medium (CM) administration.[@b6-tcrm-13-887],[@b7-tcrm-13-887] Previous studies indicated that HF is one of the critical factors influencing the development of CIN.[@b8-tcrm-13-887],[@b9-tcrm-13-887] Left ventricular ejection fraction (LVEF) is another parameter that reflects the cardiac function and a useful term to categorize the type of HF, such as HF with reduced ejection fraction (HFrEF; EF \<40%), HF with mid-range ejection fraction (HFmrEF; EF 40%--49%) and HF with preserved ejection fraction (HFpEF; EF ≥50%).[@b10-tcrm-13-887] However, the association between LVEF and the risk of CIN is still controversial.[@b11-tcrm-13-887]--[@b14-tcrm-13-887] Therefore, the purpose of our study was to analyze the association of LVEF with CIN and long-term mortality following CAG/PCI in patients with HF.

Methods
=======

Study population
----------------

This prospective observational study was conducted at the Guangdong General Hospital from April 2009 to December 2013. We included patients aged \>18 years who had HF, defined as New York Heart Association (NYHA) or Killip class \>1, and were undergoing PCI/CAG. Based on the protocol, exclusion criteria included pregnancy, malignancy, cardiovascular surgery or endovascular repair, end-stage renal disease or renal replacement, treatment with nephroprotective (eg, N-acetylcysteine) or nephrotoxic (eg, glucocorticoids, aminoglycosides) drugs and exposure to CM within the previous 7 days. In addition, patients who had missing preoperative or postoperative creatinine values (n=87) and LVEF (n=448) were excluded.

Biochemical investigations
--------------------------

Serum creatinine (SCr) concentrations were measured at admission and within 24, 48 and 72 h after CM administration. Other biochemical indicators were measured in the morning prior to the procedure. The Modification of Diet in Renal Disease equation was used to calculate the estimated glomerular filtration rate (eGFR),[@b15-tcrm-13-887] and the echocardiography examination was used to evaluate the LVEF. A baseline eGFR \<60 mL/min/1.73 m^2^ was defined as renal insufficiency.[@b16-tcrm-13-887] Furthermore, NYHA class \>2 or Killip class \>1 was defined as advanced HF.[@b17-tcrm-13-887],[@b18-tcrm-13-887]

Cardiac catheterization
-----------------------

Cardiac catheterization was performed according to the standard clinical practice, by experienced interventional cardiologists. Non-ionic, low-osmolality CM was used for all patients. The type of stents was selected by the interventional cardiologists according to operative requirements. All patients received intravenous infusion of normal saline 2--12 h before and 6--24 h after the procedure at a speed of 0.5--1.0 mL/kg/h. The hydration time and speed and the clinical medication were chosen based on the patient condition.

Clinical end points and follow-up
---------------------------------

The primary end point of this study was the development of CIN, defined as an absolute increase of ≥0.5 mg/dL or a relative increase of ≥25% from baseline SCr level within 48--72 h after CM exposure (CIN~0.5\ or\ 25%~).[@b19-tcrm-13-887] Additional end point included another criteria of CIN, defined as an absolute increase of ≥0.3 mg/dL or a relative increase of ≥50% (CIN~0.3\ or\ 50%~) and an absolute increase of ≥0.5 mg/dL (CIN~0.5~),[@b20-tcrm-13-887] and all-cause mortality.

All patients included in this study were followed up by telephone or office visits at 1, 6, 12, 24 and 36 months after discharge. Adverse events were recorded on the case report form.

This study was performed according to the Declaration of Helsinki, and the ethics committee of the Guangdong General Hospital approved the study protocol. Written informed consent was obtained from the patients involved in the study.

Statistical analysis
--------------------

Patients were divided into three groups based on the level of LVEF according to the 2016 European Society of Cardiology guideline for HF.[@b10-tcrm-13-887] For continuous variables, ANOVA was used for normally distributed data (described as mean ± standard deviation), and Wilcoxon rank-sum test was conducted for non-normal distributions (described as interquartile range). For categorical variables, *χ*^2^ test or Fisher's exact test was used (described as absolute values and percentages). Multivariable logistic regression and Cox proportional hazards regression analyses were performed to identify the association of LVEF with CIN and long-term mortality, respectively. HFpEF was considered as the reference group. The effect of HFmrEF and HFrEF on outcomes was estimated and was compared with the reference group. Kaplan--Meier method was used to describe the all-cause mortality by log-rank tests. All statistical analyses were performed with SPSS software version 22.0 (IBM Corporation, Armonk, NY, USA) and R software (version 3.1.2; R Core Team, Vienna, Austria). A two-tailed *P*\<0.05 was considered statistically significant.

Results
=======

Baseline demographics and characteristics
-----------------------------------------

A total of 1,647 patients with HF undergoing CAG/PCI were analyzed, including 207 (12.57%) patients with HFrEF, 238 (14.45%) with HFmrEF and 1,202 (72.98%) with HFpEF. The baseline demographics and characteristics of patients are listed in [Table 1](#t1-tcrm-13-887){ref-type="table"}.

Compared to the patients with HFpEF, patients with HFrEF were more likely to have advanced HF, renal insufficiency and prior myocardial fraction. Furthermore, those in the HFrEF group had lower systolic blood pressure on admission and were less likely to have a history of hyper-tension. However, age, gender, smoking, hyperlipidemia and history of coronary artery bypass grafting were similar among the three groups.

On admission, patients with HFrEF had higher SCr and N-terminal pro-brain natriuretic peptide concentrations, but lower eGFR and LVEF level. In addition, those patients were more likely to be on diuretics and less likely to be on β-blockers and stains than the other two groups. Furthermore, the prevalence of emergency PCI and the volume of CM were highest in the patients with HFmrEF.

Incidence of CIN and in-hospital outcomes
-----------------------------------------

Overall, 225 patients (13.7%) developed CIN, and the incidence of CIN0.5 or 25% was different among the LVEF groups (HFrEF, HFmrEF and HFpEF: 18.4%, 21.8% and 11.2%, respectively; *P*\<0.001). Similar trend was observed in the incidence of CIN~0.3\ or\ 50%~ or CIN~0.5~ ([Table 2](#t2-tcrm-13-887){ref-type="table"} and [Figure 1](#f1-tcrm-13-887){ref-type="fig"}).

Furthermore, patients with HFrEF were more likely to experience death (HFrEF, HFmrEF and HFpEF: 5.8%, 5.5% and 1.0%, respectively; *P*\<0.001) and hypotension (HFrEF, HFmrEF and HFpEF: 11.1%, 9.2% and 2.1%, respectively; *P*\<0.001). In addition, patients with lower LVEF had a significantly higher rate of requirement of intra-aortic balloon pump (IABP) (HFrEF, HFmrEF and HFpEF: 14.0%, 12.2% and 2.9%, respectively; *P*\<0.001) and renal replacement therapy (HFrEF, HFmrEF and HFpEF: 3.4%, 2.5% and 0.7%, respectively; *P*=0.002) ([Table 2](#t2-tcrm-13-887){ref-type="table"}).

Association of LVEF with CIN
----------------------------

After adjusting for the confounders, including age \>75 years, hypertension, diabetes mellitus, renal insufficiency, advanced HF, prior myocardial infarction, emergency PCI, CM volume \>100 mL, hypotension and use of stains, diuretics and IABP, multivariate logistic regression results revealed that individuals with lower LVEF were not at significantly increased risk of CIN compared with the highest LVEF group (HFrEF vs HFpEF: odds ratio \[OR\] =1.01, 95% confidence interval \[CI\], 0.69--1.74; *P*=0.700; HFmrEF vs HFpEF: OR =1.31, 95% CI, 0.87--1.96; *P*=0.194). Similar results were demonstrated for CIN~0.3\ or\ 50%~ or CIN~0.5~. However, age \>75 years, advanced HF, emergency PCI and use of IABP were the significantly independent risk factors for CIN in different criteria ([Table 3](#t3-tcrm-13-887){ref-type="table"}).

Association between LVEF, CIN and long-term mortality
-----------------------------------------------------

The mean follow-up period was 2.30±0.93 years. Log-rank analyses indicated that patients with lower LVEF were associated with higher mortality rate (log-rank, *P*\<0.001). The Kaplan--Meier curve is shown in [Figure 2](#f2-tcrm-13-887){ref-type="fig"}. After adjusting for the confounders which were associated with long-term mortality, multivariate Cox regression showed that HFrEF was an independent predictor of mortality (HFrEF vs HFpEF: adjusted hazard ratio \[HR\] =2.88, 95% CI, 1.77--4.69; *P*\<0.001; HFmrEF vs HFpEF: HR =1.55, 95% CI, 0.95--2.53; *P*=0.079) ([Table 4](#t4-tcrm-13-887){ref-type="table"}).

Moreover, patients who developed CIN~0.5\ or\ 25%~ had higher rate of all-cause mortality than those without during the follow-up. Similar results were found in those who developed CIN~0.3\ or\ 50%~ or CIN~0.5~ ([Figure 3](#f3-tcrm-13-887){ref-type="fig"}).

Discussion
==========

To our knowledge, this is the first study to describe the clinical characteristics and investigate the association of LVEF with CIN and long-term mortality following CAG/PCI in patients with HF. Our data showed that patients with lower LVEF were more likely to have comorbidities and develop CIN. However, advanced HF was significantly associated with an increased risk of CIN. In addition, age \>75 years, emergency PCI and use of IABP were the independent risk factors for CIN. It is noteworthy that reduced LVEF was an independent predictor of long-term mortality following CAG/PCI.

In recent years, the proportion of patients with HFpEF has increased significantly,[@b21-tcrm-13-887] with a prevalence of 71%--74% being reported in large-cohort studies from Western and Asians countries.[@b22-tcrm-13-887]--[@b24-tcrm-13-887] Additionally, myocardial ischemia has been demonstrated as the major etiology of HF.[@b25-tcrm-13-887],[@b26-tcrm-13-887] However, the incidence of HFpEF among these patients following CAG/PCI has not been analyzed. As observed in our analysis, the incidence of HFpEF was highest in the study population (72.98%), which was similar to the prior analyses. The high prevalence of HFpEF suggests that it should be given high priority in risk assessment.

Characteristics of HFmrEF were demonstrated to be intermediate between those of HFrEF and HFpEF.[@b27-tcrm-13-887] Similar results were found in the patients with HF following CAG/PCI. Our present study indicated that HFmrEF patients were closer to the HFrEF patients in terms of use of diuretics and IABP and presence of comorbidities, such as advanced HF, renal insufficiency and hypotension, but closer to the HFpEF in terms of use of statins, all of which have been demonstrated as contributing factors for CIN.[@b19-tcrm-13-887],[@b28-tcrm-13-887] Moreover, patients with HFmrEF were more likely to undergo emergency PCI than other groups. Based on those characteristics, the incidence of CIN was highest in this particular population. In recent years, CIN has been reported as the third most common cause of hospital-acquired renal failure.[@b3-tcrm-13-887] Therefore, effective pre-procedural identification of patients at high risk of CIN is vital.

LVEF is the most widely used parameter to evaluate cardiac functions associated with hemodynamic instability, and consequently causes inadequate renal perfusion. However, the association between LVEF and CIN still remains controversial. An observational study by Shacham et al[@b11-tcrm-13-887] included 386 patients undergoing PCI and found that patients with worsened LVEF had significantly higher rate of CIN compared with those with LVEF ≥45% (14.4% vs 5.7%; *P*=0.02). Moreover, worsened LVEF was an independent predictor of CIN. Similar results were found in another extensive cohort study, and a risk score of CIN was named AGEF, including advanced age, depressed LVEF and reduced eGFR.[@b12-tcrm-13-887],[@b29-tcrm-13-887] However, studies conducted by Kurtul et al[@b13-tcrm-13-887] and Barbieri et al[@b14-tcrm-13-887] showed an opposite effect after adjusting for several confounders. As observed in all the above-mentioned studies, only a small number of patients with HF were included, and consequently, those studies were unable to analyze the association between LVEF and CIN. Furthermore, HF, as an important risk factor of CIN,[@b8-tcrm-13-887],[@b19-tcrm-13-887] was not included in the multivariate analysis. In contrast, our study included sufficient patients with HF and adjusted for the potential confounders to investigate the association of LVEF with CIN following CAG/PCI.

Previous studies indicated that the incidence of CIN in those with segment elevation myocardial infarction after PCI to be ranged from 10% to 20%. The potential factors such as impaired hemodynamic stability, large CM dose and insufficient prophylactic hydration led to higher risk of CIN in this particular group. In addition, inflammatory response and neurohumoral factors were also involved in this progress.[@b30-tcrm-13-887] Therefore, emergency PCI was significantly and independently related to the risk of CIN.[@b31-tcrm-13-887],[@b32-tcrm-13-887] Recently, Duan et al[@b33-tcrm-13-887] developed a simple model for early prediction of CIN, which indicated that emergency PCI was a significant influencing factor in this model. Similarly, emergency PCI increased the risk of CIN in our analysis. Therefore, more prophylactic measures and attention should be paid in this particular population.

The physiopathology of CIN remains poorly understood. Nevertheless, hemodynamic deterioration plays a significant role in the process. Worsened cardiac function contributes to the hemodynamic instability, which reduces effective renal blood flow, consequently trigging renin--angiotensin, activating sympathetic nervous system and increasing inflammatory factors and oxygen radical levels, all of which contribute to the development of CIN.[@b34-tcrm-13-887] Therefore, among the eight variables from a classical risk assessment model for CIN, three (hypotension, advanced HF and use of IABP) are directly reflecting worsened cardiac function.[@b8-tcrm-13-887] In addition, a high NYHA class reflects not only advanced HF but also adverse hemodynamic parameters[@b35-tcrm-13-887] which accelerate the renal hypoperfusion and potentiate CIN. Therefore, it is likely that advanced HF plays an important role in the development of CIN in patients with HF.

Furthermore, previous studies suggested that patients with HFrEF experienced higher mortality compared to those with HFpEF, whereas others have indicated similar outcomes among the groups.[@b36-tcrm-13-887]--[@b38-tcrm-13-887] The marked disparity in long-term prognosis may contribute to the different inclusion criteria and various cut-offs of LVEF to define the type of HF. According to the classification of HF from guideline,[@b10-tcrm-13-887] our data demonstrated that HFrEF in patients increased the risk of all-cause mortality. Therefore, early identification of patients at high risk of mortality may assist in directing treatment.

Limitations
-----------

There are several limitations in this study. First, this was a prospective, observational and a single-center study. Therefore, the risk of bias cannot be ruled out, although we attempted to adjust for the confounding factors. Therefore, large-scale multicenter clinical trials are needed before these conclusions can be applied elsewhere. Second, variation in measurement times may lead to missed post-procedure peak levels of creatinine and may underestimate the true incidence of contrast-induced acute kidney injury. Third, as the study was limited to patients with HF, we were unable to extend the results to patients without HF. Fourth, the diagnosis of HF was based on the clinical evaluation, which has limited reliability.

Conclusion
==========

Our data indicated that in patients with HF, not worsened LVEF but advanced HF was significantly associated with an increased risk of CIN following CAG/PCI. In addition, the reduced LVEF (HFrEF group) was an independent predictor of long-term mortality. The predictive value of worsened LVEF and advanced HF for CIN and mortality following cardiac catheterization needs to be investigated in patients with HF in large multicenter clinical trials.
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###### 

Baseline characteristics according to the left ventricular ejection fraction group

  Variables                                     HFrEF (N=207)       HFmrEF (N=238)      HFpEF (N=1,202)     *P*-values
  --------------------------------------------- ------------------- ------------------- ------------------- ------------
  Demographics                                                                                              
   Age (years)                                  64.20±10.75         65.05±11.44         64.90±10.52         0.651
   Female (%)                                   43 (20.8)           51 (21.4)           319 (26.5)          0.078
   SBP (mmHg)                                   122.62±20.49        123.99±20.65        132.50±20.61        \<0.001
   DBP (mmHg)                                   76.65±12.03         73.98±12.80         76.16±11.78         0.023
   Advanced HF, n (%)                           115 (55.6)          115 (48.3)          271 (22.5)          \<0.001
  Medical history, n (%)                                                                                    
   Smoking                                      84 (40.6)           106 (44.5)          442 (36.8)          0.062
   Hypertension                                 98 (47.3)           136 (57.1)          775 (64.5)          \<0.001
   Diabetes mellitus                            57 (27.5)           64 (26.9)           311 (25.9)          0.854
   Hyperlipidemia                               26 (12.6)           26 (10.9)           175 (14.6)          0.286
   Prior MI                                     44 (21.3)           55 (23.1)           103 (8.6)           \<0.001
   Prior CABG                                   2 (1.0)             3 (1.3)             12 (1.0)            0.931
   Renal insufficiency                          71 (34.3)           75 (31.5)           239 (19.9)          \<0.001
  Laboratory index                                                                                          
   SCr (µmol/L)                                 107.50±46.41        101.84±37.05        91.65±33.06         \<0.001
   eGFR (mL/min/1.73 m^2^)                      70.88±25.99         73.39±26.11         79.79±25.01         \<0.001
   NT-proBNP (pg/mL)                            5,050.16±6,454.23   2,844.92±4,201.42   1,108.34±3,421.70   \<0.001
   LVEF (%)                                     32.01±5.74          44.49±3.00          63.48±6.94          \<0.001
   TG (mmol/L)                                  1.31±0.82           1.41±0.69           1.55±1.25           0.072
   CHO (mmol/L)                                 4.29±1.05           4.50±1.11           4.39±1.16           0.361
   LDL (mmol/L)                                 2.57±0.84           2.81±0.94           2.61±0.95           0.071
   HDL (mmol/L)                                 0.94±0.29           0.87±0.25           1.03±2.47           0.721
   HbA1c (%)                                    6.74±1.38           6.80±1.60           6.55±1.31           0.030
   HGB (g/L)                                    132.41±17.98        131.17±17.65        131.50±16.56        0.749
   Anemia, n (%)                                67 (32.4)           94 (39.5)           420 (34.9)          0.262
  Perioperative medications, n (%)                                                                          
   ACEI/ARB                                     181 (87.4)          206 (86.6)          1,053 (87.6)        0.905
   β-blockers                                   157 (75.8)          198 (83.2)          1,015 (84.4)        0.009
   Statins                                      192 (92.8)          230 (96.6)          1,160 (96.5)        0.033
   Diuretics                                    116 (56.0)          97 (40.8)           176 (14.6)          \<0.001
  Angiographic and procedural characteristics                                                               
   Emergent PCI, n (%)                          36 (17.4)           64 (26.9)           126 (10.5)          \<0.001
   CM volume (mL)                               124.30±69.76        140.11±69.99        133.84±66.49        0.046
   CM volume \>100 mL                           101 (48.8)          144 (60.5)          687 (57.2)          0.034
   Stents length (mm)                           32.69±36.07         39.91±37.48         37.22±33.02         0.078
   Hydration volume mL                          855.19±536.83       894.70±492.87       801.85±464.86       0.014
   Mehran risk score                            8.76±6.09           8.85±5.62           5.86±4.33           \<0.001

**Abbreviations:** HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; SBP, systolic blood pressure; DBP, diastolic blood pressure; HF, heart failure; MI, myocardial infarction; CABG, coronary artery bypass grafting; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; LVEF, left ventricular ejection fraction; TG, triglyceride; CHO, cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HbA1c, hemoglobin A1c; HGB, hemoglobin; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; PCI, percutaneous coronary intervention; CM, contrast medium.

###### 

Incidence of CIN and in-hospital outcomes between left ventricular ejection fraction groups

  ----------------------------------------------------------------------------
  Variables, n (%)            HFrEF\      HFmrEF\     HFpEF\       *P*-value
                              (N=207)     (N=238)     (N=1,202)    
  --------------------------- ----------- ----------- ------------ -----------
  CIN~0.5\ or\ 25%~           38 (18.4)   52 (21.8)   135 (11.2)   \<0.001

  CIN~0.3\ or\ 50%~           29 (14.0)   38 (16.0)   78 (6.5)     \<0.001

  CIN~0.5~                    16 (7.7)    22 (9.2)    37 (3.1)     \<0.001

  Death                       12 (5.8)    13 (5.5)    12 (1.0)     \<0.001

  Hypotension                 23 (11.1)   22 (9.2)    25 (2.1)     \<0.001

  Intra-aortic balloon pump   29 (14.0)   29 (12.2)   35 (2.9)     \<0.001

  Renal replacement therapy   7 (3.4)     6 (2.5)     9 (0.7)      0.002

  Cerebrovascular events      2 (1.0)     3 (1.3)     7 (0.6)      0.485
  ----------------------------------------------------------------------------

**Abbreviations:** CIN, contrast-induced nephropathy; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction.

###### 

Association of left ventricular ejection fraction with CIN in different definition

  Variables             CIN~0.5\ or\ 25%~   CIN~0.3\ or\ 50%~   CIN~0.5~                                                     
  --------------------- ------------------- ------------------- ---------- ------ ------------ --------- ------ ------------ ---------
  HFpEF                 1                   Reference           --         1      Reference    --        1      Reference    --
  HFrEF vs HFpEF        1.01                0.69--1.74          0.700      1.13   0.64--1.97   0.676     1.10   0.53--2.31   0.799
  HFmrEF vs HFpEF       1.31                0.87--1.96          0.194      1.43   0.88--2.33   0.145     1.58   0.84--2.98   0.158
  Age \>75 years        1.73                1.20--2.49          0.004      1.77   1.51--2.72   0.010     2.07   1.18--3.62   0.011
  Hypertension          1.20                0.86--1.65          0.280      1.52   0.98--2.33   0.059     1.41   0.78--2.56   0.253
  DM                    1.08                0.77--1.52          0.644      0.79   0.51--1.22   0.289     0.64   0.35--1.17   0.146
  Renal insufficiency   0.73                0.50--1.06          0.094      2.32   1.54--3.49   \<0.001   3.59   2.05--6.27   \<0.001
  Advanced HF           1.54                1.07--2.22          0.019      1.63   1.03--2.58   0.036     2.03   1.06--3.89   0.033
  Prior MI              0.90                0.55--1.48          0.685      0.80   0.42--1.53   0.505     0.61   0.23--1.57   0.303
  Emergency PCI         2.83                1.93--4.14          \<0.001    2.80   1.78--4.40   \<0.001   2.93   1.63--5.28   \<0.001
  Stains                0.71                0.34--1.47          0.351      0.36   0.16--0.78   0.009     0.23   0.09--0.59   0.002
  Diuretics             1.73                1.21--2.47          0.003      1.80   1.17--2.77   0.007     1.41   0.79--2.51   0.243
  CM volume \>100 mL    1.21                0.89--1.66          0.223      1.36   0.91--2.03   0.134     1.52   0.87--2.65   0.142
  Hypotension           1.28                0.68--2.39          0.445      1.67   0.85--3.31   0.138     2.29   1.04--5.04   0.04
  IABP                  2.45                1.44--4.19          \<0.001    3.65   2.08--6.40   \<0.001   3.83   1.95--7.51   \<0.001

**Abbreviations:** CIN, contrast-induced nephropathy; OR, odds ratio; CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; DM, diabetes mellitus; HF, heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention; CM, contrast medium; IABP, intra-aortic balloon pump.

###### 

Association between left ventricular ejection fraction and long-term mortality

  Variables             Univariate   Multivariate                                 
  --------------------- ------------ -------------- --------- ------ ------------ ---------
  HFpEF                 1            Reference      --        1      Reference    --
  HFrEF vs HFpEF        3.42         2.9--5.35      \<0.001   2.88   1.77--4.69   \<0.001
  HFmrEF vs HFpEF       2.22         1.39--3.55     \<0.001   1.55   0.95--2.53   0.079
  Age \>75 years        2.52         1.69--3.76     \<0.001   1.76   1.14--2.72   0.011
  Hypertension          1.00         0.68--1.46     0.998     0.91   0.61--1.37   0.66
  Renal insufficiency   4.55         3.14--6.60     \<0.001   3.04   2.02--4.56   \<0.001
  DM                    1.61         1.09--2.37     0.017     1.38   0.93--2.07   0.113
  IABP                  4.66         2.90--7.49     \<0.001   2.00   1.18--3.38   0.01
  Advanced HF           2.19         1.51--3.17     \<0.001   0.83   0.53--1.30   0.409
  Anemia                2.04         1.41--2.96     \<0.001   1.46   0.99--2.17   0.056
  Emergency PCI         3.35         2.25--5.00     \<0.001   2.49   1.55--4.00   \<0.001

**Abbreviations:** HR, hazard ratio; CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; DM, diabetes mellitus; IABP, intra-aortic balloon pump; HF, heart failure; PCI, percutaneous coronary intervention.
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